2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused a 10-day decline in biotech ETFs. StockWatch’s top five performing biotech stocks include Bright Minds Biosciences and Monopar Therapeutics while the biggest laggards were Aditxt and CNS Pharmaceuticals. Mesoblast’s American Depositary Receipts rose significantly due to FDA approval of its Ryoncil treatment.
Healthcare Sector Emerges as a Prime Target for Cyber Attacks in 2025
In 2025, healthcare institutions face escalating cyber threats, particularly from malware distributed via trusted platforms like GitHub. Attackers exploit cloud infrastructures and disguise malicious code
